DOCSLIB.ORG

Cellular Pathophysiological Consequences of BCS1L Mutations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cellular Pathophysiological Consequences of BCS1L Mutations Cellular pathophysiological consequences of BCS1L mutations in mitochondrial complex III enzyme deficiency Maria Moran, Lorena Marín Buera, Maria Carmen Gil, Henry Rivera, Alberto Blazquez, Sara Seneca, Maria Vazquez Lopez, Joaquin Arenas, Miguel A Martin, Cristina Ugalde To cite this version: Maria Moran, Lorena Marín Buera, Maria Carmen Gil, Henry Rivera, Alberto Blazquez, et al.. Cel- lular pathophysiological consequences of BCS1L mutations in mitochondrial complex III enzyme de- ficiency. Human Mutation, Wiley, 2010, 31 (8), pp.930. 10.1002/humu.21294. hal-00552400 HAL Id: hal-00552400 https://hal.archives-ouvertes.fr/hal-00552400 Submitted on 6 Jan 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Human Mutation Cellular pathophysiological consequences of BCS1L mutations in mitochondrial complex III enzyme deficiency For Peer Review Journal: Human Mutation Manuscript ID: humu-2010-0090.R1 Wiley - Manuscript type: Research Article Date Submitted by the 23-Apr-2010 Author: Complete List of Authors: Moran, Maria; Hospital Universitario 12 de Octubre, Centro de Investigacion Marín Buera, Lorena; Hospital Universitario 12 de Octubre, Centro de Investigacion Gil, Maria Carmen; Hospital Universitario 12 de Octubre, Centro de Investigacion Rivera, Henry; Hospital Universitario 12 de Octubre, Centro de Investigacion Blazquez, Alberto; Hospital Universitario 12 de Octubre, Centro de Investigacion Seneca, Sara; AZ-VUB, Center of Medical Genetics Vazquez Lopez, Maria; Hospital General Universitario Gregorio Marañón, Sección de Neuropediatría Arenas, Joaquin; Hospital Universitario 12 de Octubre, Centro de Investigación; Hospital Universitario 12 de Octubre, Centro de Investigacion Martin, Miguel; Hospital Universitario 12 de Octubre, Centro de Investigación; Hospital Universitario 12 de Octubre, Centro de Investigacion Ugalde, Cristina; Hospital Universitario 12 de Octubre, Centro de Investigacion Mitochondria, Respiratory chain , Complex III deficiency, BCS1L Key Words: mutations John Wiley & Sons, Inc. Page 1 of 44 Human Mutation Morán et al. 1 1 2 3 Cellular pathophysiological consequences of BCS1L mutations in mitochondrial 4 5 6 complex III enzyme deficiency 7 8 María Morán, 1,2,* Lorena Marín-Buera, 1,2,* M. Carmen Gil-Borlado, 1,2 Henry Rivera, 1,2 9 10 Alberto Blázquez, 1,2 Sara Seneca, 3 María Vázquez-López,4 Joaquín Arenas, 1,2 Miguel 11 12 1,2 1,2 13 A. Martín, and Cristina Ugalde 14 15 16 17 18 * These authors equally contributed to this work 19 20 For Peer Review 21 22 1Centro de Investigación, Hospital Universitario 12 de Octubre, Madrid, Spain; 2Centro 23 24 25 de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Spain; 26 27 3Center of Medical Genetics, AZ-VUB, Brussels, Belgium; and 4Sección de 28 29 Neuropediatría, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 30 31 32 33 34 Corresponding author: Dr. Cristina Ugalde, Centro de Investigación, Hospital 35 36 Universitario 12 de Octubre. Avda. de Córdoba s/n. 28041 Madrid. Phone: +34 91 390 37 38 39 8763, FAX: +34 91 390 8544, e-mail: [email protected] 40 41 42 43 44 Abbreviated title: Role of mutated BCS1L in complex III deficiency 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 John Wiley & Sons, Inc. Human Mutation Page 2 of 44 Morán et al. 2 1 2 3 ABSTRACT 4 5 6 Mutations in BCS1L, an assembly factor that facilitates the insertion of the 7 8 catalytic Rieske Iron-Sulphur subunit into respiratory chain complex III, result in a wide 9 10 variety of clinical phenotypes that range from the relatively mild Björnstad syndrome, to 11 12 13 the severe GRACILE syndrome. To better understand the pathophysiological 14 15 consequences of such mutations, we studied fibroblasts from six complex III-deficient 16 17 18 patients harbouring mutations in the BCS1L gene. Cells from patients with the most 19 20 severe clinical phenotypesFor exhibited Peer slow growth Review rates in glucose medium, variable 21 22 combined enzyme deficiencies and assembly defects of respiratory chain complexes I, 23 24 25 III and IV, increased H2O2 levels, unbalanced expression of the cellular antioxidant 26 27 defences, and apoptotic cell death induction. Besides, all patients showed cytosolic 28 29 accumulation of the BCS1L protein, suggestive of an impaired mitochondrial import, 30 31 32 assembly or stability defects of the BCS1L complex, fragmentation of the mitochondrial 33 34 networks, and decreased MFN2 protein levels. The observed structural alterations were 35 36 independent of the respiratory chain function and ROS production. Our results provide 37 38 39 new insights into the role of pathogenic BCS1L mutations in mitochondrial function and 40 41 dynamics. 42 43 44 45 46 KEYWORDS: Mitochondria; respiratory chain complex III deficiency; BCS1L 47 48 mutations. 49 50 51 52 53 54 55 56 57 58 59 60 John Wiley & Sons, Inc. Page 3 of 44 Human Mutation Morán et al. 3 1 2 3 INTRODUCTION 4 5 6 Mitochondrial respiratory chain complex III (CIII, ubiquinol-cytochrome c 7 8 oxidoreductase or cytochrome bc1 complex, E.C.1.10.2.2) catalyzes the transfer of 9 10 electrons from reduced coenzyme Q to cytochrome c with a concomitant translocation 11 12 13 of protons across the inner membrane (Baum et al., 1967). The purified bovine complex 14 15 is a ~450 kDa symmetric homodimer (Iwata 1998; Xia et al., 1997). Each monomer is 16 17 18 composed of eight structural subunits, and three catalytic subunits: cytochrome b, the 19 20 only subunit encodedFor in the mitochondrial Peer genome, Review cytochrome c1, and the Rieske Iron- 21 22 Sulphur Protein (RISP). 23 24 25 Mitochondrial complex III enzyme deficiency (MIM #124000 ) is a relatively 26 27 infrequent diagnosed defect of the oxidative phosphorylation (OXPHOS) system (Benit 28 29 30 et al., 2009). The vast majority of nuclear mutations leading to complex III deficiency 31 32 have been reported in the BCS1L gene (MIM #603647), which encodes a mitochondrial 33 34 inner membrane protein necessary for the correct biogenesis of respiratory chain 35 36 37 complex III (Cruciat et al., 1999; Fernandez-Vizarra et al., 2007; Fernandez-Vizarra et 38 39 al., 2009; Nobrega et al., 1992). BCS1L mutations lead to three main clinical 40 41 ) 42 phenotypes (Ramos-Arroyo et al., 2009): i) Björnstad syndrome (MIM #262000 , an 43 44 autosomal recessive disorder characterized by sensorineural hearing loss and pili torti 45 46 ( 47 (Hinson et al., 2007); ii) GRACILE syndrome MIM #603358), a Finnish-heritage 48 49 disease caused by the homozygous p.S78G mutation (Fellman 2002; Visapaa et al., 50 51 2002), which is characterized by fetal growth retardation, aminoaciduria, cholestasis, 52 53 54 iron overload, lactic acidosis, and early death; and iii) complex III deficiency in 55 56 neonates or infants presenting with encephalopathy, alone or in combination with 57 58 visceral involvement (Blazquez et al., 2009; de Lonlay et al., 2001; De Meirleir et al., 59 60 2003; Fernandez-Vizarra et al., 2007; Gil-Borlado et al., 2009). John Wiley & Sons, Inc. Human Mutation Page 4 of 44 Morán et al. 4 1 2 3 Human BCS1L protein consists of 419 aminoacids, and shares functional 4 5 6 homology and 50% identity with yeast Bcs1p (Nobrega et al., 1992; Petruzzella et al., 7 8 1998) . In yeast, Bcs1p acts as an ATP-dependent chaperone, maintaining pre-complex 9 10 III in a competent state for the subsequent assembly of the Rieske and Qcr10 subunits 11 12 13 (Cruciat et al., 1999). The absence of Bcs1p prevents the assembly of Rieske within 14 15 complex III and leads to a complete respiratory deficiency. Bcs1p spans three different 16 17 18 domains: i) the N-terminal domain comprises aminoacid residues 1 to 126, which 19 20 contain all the requiredFor information Peer for the mitochondrialReview targeting and sorting of the 21 22 protein (Folsch et al., 1996; Petruzzella et al., 1998); ii) a Bcs1p-specific domain 23 24 25 contains aminoacid residues that are important for Bcs1p activity and stability (Nouet et 26 27 al., 2009); and iii) the C-terminal region contains a ~200 aminoacids domain that 28 29 encompasses two motifs corresponding to nucleotide binding sites, a characteristic 30 31 32 feature of the AAA (for ATPases associated with various cellular activities) protein 33 34 superfamily (Frickey and Lupas, 2004). 35 36 Pathogenic mutations have been described in the three different domains of 37 38 39 human BCS1L, although the pathophysiological mechanisms that contribute to the 40 41 clinical manifestations of the disease remain poorly understood. In some BCS1L - 42 43 44 mutated patients presenting with Björnstad syndrome or complex III deficiency, an 45 46 assembly defect of the RISP subunit led to a mitochondrial complex III enzyme defect 47 48 (Blazquez et al., 2009; Fernandez-Vizarra et al., 2007; Gil-Borlado et al., 2009; Hinson 49 50 51 et al., 2007). However, in patients presenting with the characteristic BCS1L mutation 52 53 c.232A>G (p.S78G) leading to GRACILE syndrome, complex III activity was 54 55 essentially normal despite low BCS1L levels (Fellman et al., 2008). Iron overload has 56 57 58 been reported in some patients with BCS1L mutations leading to GRACILE syndrome 59 60 or complex III deficiency, but not Björnstad Syndrome, suggesting a second hypothetic role for BCS1L in iron metabolism (De Meirleir et al., 2003; Visapaa et al., 2002).
Load more

Recommended publications
  • Supplement 1 Overview of Dystonia Genes
    Supplement 1 Overview of genes that may cause dystonia in children and adolescents Gene (OMIM) Disease name/phenotype Mode of inheritance 1: (Formerly called) Primary dystonias (DYTs): TOR1A (605204) DYT1: Early-onset generalized AD primary torsion dystonia (PTD) TUBB4A (602662) DYT4: Whispering dystonia AD GCH1 (600225) DYT5: GTP-cyclohydrolase 1 AD deficiency THAP1 (609520) DYT6: Adolescent onset torsion AD dystonia, mixed type PNKD/MR1 (609023) DYT8: Paroxysmal non- AD kinesigenic dyskinesia SLC2A1 (138140) DYT9/18: Paroxysmal choreoathetosis with episodic AD ataxia and spasticity/GLUT1 deficiency syndrome-1 PRRT2 (614386) DYT10: Paroxysmal kinesigenic AD dyskinesia SGCE (604149) DYT11: Myoclonus-dystonia AD ATP1A3 (182350) DYT12: Rapid-onset dystonia AD parkinsonism PRKRA (603424) DYT16: Young-onset dystonia AR parkinsonism ANO3 (610110) DYT24: Primary focal dystonia AD GNAL (139312) DYT25: Primary torsion dystonia AD 2: Inborn errors of metabolism: GCDH (608801) Glutaric aciduria type 1 AR PCCA (232000) Propionic aciduria AR PCCB (232050) Propionic aciduria AR MUT (609058) Methylmalonic aciduria AR MMAA (607481) Cobalamin A deficiency AR MMAB (607568) Cobalamin B deficiency AR MMACHC (609831) Cobalamin C deficiency AR C2orf25 (611935) Cobalamin D deficiency AR MTRR (602568) Cobalamin E deficiency AR LMBRD1 (612625) Cobalamin F deficiency AR MTR (156570) Cobalamin G deficiency AR CBS (613381) Homocysteinuria AR PCBD (126090) Hyperphelaninemia variant D AR TH (191290) Tyrosine hydroxylase deficiency AR SPR (182125) Sepiaterine reductase
    [Show full text]
  • Using Chemical Inhibitors to Probe AAA Protein Conformational Dynamics and Cellular Functions Steinman and Kapoor 47
    Available online at www.sciencedirect.com ScienceDirect Using chemical inhibitors to probe AAA protein conformational dynamics and cellular functions Jonathan B Steinman and Tarun M Kapoor The AAA proteins are a family of enzymes that play key roles in shRNA) can often take longer than many of the cellular diverse dynamic cellular processes, ranging from proteostasis processes they are involved in and thereby lead to the to directional intracellular transport. Dysregulation of AAA accumulation of phenotypes not directly linked to their proteins has been linked to several diseases, including cancer, functions. Destabilization of multi-protein complexes also suggesting a possible therapeutic role for inhibitors of these has the potential to cause dominant negative effects. Simi- enzymes. In the past decade, new chemical probes have been larly, the slowly or non-hydrolyzable ATP analogs often used developed for AAA proteins including p97, dynein, midasin, and to study AAA proteins in vitro are poorly suited for studying ClpC1. In this review, we discuss how these compounds have these enzymes in cellular contexts, as they are generally been used to study the cellular functions and conformational unable to cross cell membranes and tend to inhibit multiple dynamics of AAA proteins. We discuss future directions for different enzymes. inhibitor development and early efforts to utilize AAA protein inhibitors in the clinical setting. Cell-permeable chemical inhibitors of AAA proteins have the potential to overcome many of these challenges. They Address can act on timescales that match the processes driven by Laboratory of Chemistry and Cell Biology, Rockefeller University, New these enzymes, limiting the degree to which cells can York, United States activate compensatory pathways or accumulate indirect Corresponding author: Kapoor, Tarun M ([email protected]) effects.
    [Show full text]
  • Blueprint Genetics BCS1L Single Gene Test
    BCS1L single gene test Test code: S00213 Phenotype information Bjornstad syndrome GRACILE syndrome Leigh syndrome Mitochondrial complex III deficiency, nuclear type 1 Alternative gene names BCS, BJS, Hs.6719, h-BCS Panels that include the BCS1L gene Syndromic Hearing Loss Panel Comprehensive Hearing Loss and Deafness Panel Resonate Program Panel 3-M Syndrome / Primordial Dwarfism Panel Ectodermal Dysplasia Panel Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel Comprehensive Metabolism Panel Organic Acidemia/Aciduria & Cobalamin Deficiency Panel Comprehensive Short Stature Syndrome Panel Non-coding disease causing variants covered by the test Gene Genomic location HG19 HGVS RefSeq RS-number BCS1L Chr2:219524871 c.-147A>G NM_004328.4 BCS1L Chr2:219525123 c.-50+155T>A NM_004328.4 rs386833855 Test Strengths The strengths of this test include: CAP accredited laboratory CLIA-certified personnel performing clinical testing in a CLIA-certified laboratory Powerful sequencing technologies, advanced target enrichment methods and precision bioinformatics pipelines ensure superior analytical performance Careful construction of clinically effective and scientifically justified gene panels Our Nucleus online portal providing transparent and easy access to quality and performance data at the patient level Our publicly available analytic validation demonstrating complete details of test performance ~2,000 non-coding disease causing variants in our clinical grade NGS assay for panels (please see ‘Non-coding disease causing variants
    [Show full text]
  • A Double-Hexameric MCM2-7 Complex Is Loaded Onto Origin DNA During Licensing of Eukaryotic DNA Replication
    A double-hexameric MCM2-7 complex is loaded onto origin DNA during licensing of eukaryotic DNA replication Cecile Evrina, Pippa Clarkea, Juergen Zecha, Rudi Lurzb, Jingchuan Sunc, Stefan Uhlea,1, Huilin Lic, Bruce Stillmand,2, and Christian Specka,2 aDNA Replication Group, Medical Research Council Clinical Sciences Centre, Imperial College London, London W12 0NN, United Kingdom; bMicroscopy Unit, Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany; cBiology Department, Brookhaven National Laboratory, Upton, NY 11973; and dCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724 Contributed by Bruce Stillman, October 6, 2009 (sent for review September 22, 2009) During pre-replication complex (pre-RC) formation, origin recog- to form the pre-initiation complex (pre-IC). Binding of pre-IC nition complex (ORC), Cdc6, and Cdt1 cooperatively load the proteins and protein kinase activity stimulates MCM2-7 helicase 6-subunit mini chromosome maintenance (MCM2-7) complex onto activity (13). Pre-IC formation culminates in the recruitment of DNA. Loading of MCM2-7 is a prerequisite for DNA licensing that DNA polymerases and the start of active DNA replication (14). restricts DNA replication to once per cell cycle. During S phase ORC and Cdc6 belong to the AAAϩ family of ATP binding MCM2-7 functions as part of the replicative helicase but within the proteins (4, 15), a family that commonly forms ring- or spiral- pre-RC MCM2-7 is inactive. The organization of replicative DNA shaped structures. A spiral-shaped structure consisting of 5 helicases before and after loading onto DNA has been studied in AAAϩ proteins within the replication factor C (RFC) complex bacteria and viruses but not eukaryotes and is of major importance functions to destabilize the homotrimeric proliferating cell nu- for understanding the MCM2-7 loading mechanism and replisome clear antigen (PCNA) ring during PCNA loading onto DNA.
    [Show full text]
  • Relationships Between Expression of BCS1L, Mitochondrial Bioenergetics, and Fatigue Among Patients with Prostate Cancer
    Cancer Management and Research Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Relationships between expression of BCS1L, mitochondrial bioenergetics, and fatigue among patients with prostate cancer This article was published in the following Dove Press journal: Cancer Management and Research Chao-Pin Hsiao1,2 Introduction: Cancer-related fatigue (CRF) is the most debilitating symptom with the Mei-Kuang Chen3 greatest adverse side effect on quality of life. The etiology of this symptom is still not Martina L Veigl4 understood. The purpose of this study was to examine the relationship between mitochon- Rodney Ellis5 drial gene expression, mitochondrial oxidative phosphorylation, electron transport chain Matthew Cooney6 complex activity, and fatigue in prostate cancer patients undergoing radiotherapy (XRT), Barbara Daly1 compared to patients on active surveillance (AS). Methods: The study used a matched case–control and repeated-measures research design. Charles Hoppel7 Fatigue was measured using the revised Piper Fatigue Scale from 52 patients with prostate 1The Frances Payne Bolton School of cancer. Mitochondrial oxidative phosphorylation, electron-transport chain enzymatic activity, Nursing, Case Western Reserve ’ University, Cleveland, OH, USA; 2School and BCS1L gene expression were determined using patients peripheral mononuclear cells. of Nursing, Taipei Medical University, Data were collected at three time points and analyzed using repeated measures ANOVA. 3 Taipei , Taiwan; Department of Results: The fatigue score was significantly different over time between patients undergoing XRT Psychology, University of Arizona, fi Tucson, AZ, USA; 4Gene Expression & and AS (P<0.05). Patients undergoing XRT experienced signi cantly increased fatigue at day 21 Genotyping Facility, Case Comprehensive and day 42 of XRT (P<0.01).
    [Show full text]
  • Apoptosis Induced by Microinjection of Cytochrome C Is Caspase-Dependent and Is Inhibited by Bcl-2
    Cell Death and Differentiation (1998) 5, 660 ± 668 1998 Stockton Press All rights reserved 13509047/98 $12.00 http://www.stockton-press.co.uk/cdd Apoptosis induced by microinjection of cytochrome c is caspase-dependent and is inhibited by Bcl-2 Odd T. Brustugun1, Kari E. Fladmark1, Stein O. Dùskeland1,3, proteins, chromatin and RNA degradation, cell shrinkage and Sten Orrenius2 and Boris Zhivotovsky2 blebbing of cell membranes accompanied by the appearance of phosphatidyl serine on the outer surface of the plasma 1 Department of Anatomy and Cell Biology, University of Bergen, AÊ rstadveien 19, membrane. N-5009 Bergen, Norway The biochemical machinery involved in the killing and 2 Institute of Environmental Medicine, Division of Toxicology, Karolinska degradation of the cell is constitutively expressed. During Institutet, Box 210, S-171 77 Stockholm, Sweden the last few years the `main players' in the induction and 3 corresponding author: Department of Anatomy and Cell Biology, University of execution cascade of reactions in apoptotic cells were Bergen, AÊ rstadveien 19, N-5009 Bergen, Norway. tel: +47 55 58 63 76; fax: +47 55 58 63 60; e-mail: [email protected] identified as a family of aspartic acid-specific cysteine proteases, the caspases (Alnemri et al, 1996). Over- Received 26.11.97; revised 2.3.98; accepted 23.3.98 expression of any of these proteases leads to apoptotic Edited by G. Melino cell death. Moreover, mice deficient in caspase-3 have a striking defect in the extensive apoptosis that occurs during brain development. Peptide inhibitors of caspases can Abstract prevent apoptosis both in isolated cells and in in vivo Microinjection of cytochrome c induced apoptosis in all the models of development.
    [Show full text]
  • Bax Transmembrane Domain Interacts with Prosurvival Bcl-2 Proteins in Biological Membranes
    Bax transmembrane domain interacts with prosurvival Bcl-2 proteins in biological membranes Vicente Andreu-Fernándeza,b,c, Mónica Sanchoa, Ainhoa Genovésa, Estefanía Lucendoa, Franziska Todtb, Joachim Lauterwasserb,d, Kathrin Funkb,d, Günther Jahreise, Enrique Pérez-Payáa,f,1, Ismael Mingarroc,2, Frank Edlichb,g,2, and Mar Orzáeza,2 aLaboratory of Peptide and Protein Chemistry, Centro de Investigación Príncipe Felipe, E-46012 Valencia, Spain; bInstitute for Biochemistry and Molecular Biology, University of Freiburg, 79104 Freiburg, Germany; cDepartament de Bioquímica i Biologia Molecular, Estructura de Recerca Interdisciplinar en Biotecnología i Biomedicina, Universitat de València, 46100 Burjassot, Spain; dFaculty of Biology, University of Freiburg, 79104 Freiburg, Germany; eDepartment of Biochemistry/Biotechnology, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany; fInstituto de Biomedicina de Valencia, Instituto de Biomedicina de Valencia–Consejo Superior de Investigaciones Científicas, 46010 Valencia, Spain; and gBIOSS, Centre for Biological Signaling Studies, University of Freiburg, 79104 Freiburg, Germany Edited by William F. DeGrado, School of Pharmacy, University of California, San Francisco, CA, and approved November 29, 2016 (received for review July 28, 2016) The Bcl-2 (B-cell lymphoma 2) protein Bax (Bcl-2 associated X, across bilayers via changes in the oligomeric state or protein con- apoptosis regulator) can commit cells to apoptosis via outer mito- formation (22–24). The Bax TMD targets fusion proteins to the chondrial membrane permeabilization. Bax activity is controlled in OMM; its deletion results in cytosolic Bax localization and impaired healthy cells by prosurvival Bcl-2 proteins. C-terminal Bax trans- Bax activity (25). Analysis of the active Bax membrane topology membrane domain interactions were implicated recently in Bax pore suggests that the TMD could play a central role in Bax oligomeri- formation.
    [Show full text]
  • Pyruvate Dehydrogenase Deficiency in a Child with Motor Neuropathy
    003 1-399819313303-0284$03.00/0 PEDIATRIC RESEARCH Vol. 33, No. 3, 1993 Copyright O 1993 International Pediatric Research Foundation, Inc. Prinled in U.S.A. Pyruvate Dehydrogenase Deficiency in a Child with Motor Neuropathy GISELE BONNE, CHANTAL BENELLI, LINDA DE MEIRLEIR, WILLY LISSENS, MICHELE CHAUSSAIN, MONIQUE DIRY, JEAN-PIERRE CLOT, GERARD PONSOT, VALERIE GEOFFROY, JEAN-PAUL LEROUX, AND CECILE MARSAC INSERM U 75, Faculte Neclter, 75015 Paris, France[G.B., M.D., J.P.L., C.M.], INSERM U 30, H6pital Neclter, 75015 Puri.~,France [C.B., J-P.C., V.G.];Lahoraroire de GenPtique, Vrije Universili Bruxelles, 1090 Bruxelles, Belgiz~rn[L.D.M., W.L.];and N6pital Saint Vincent de Paul, 75014 Paris, France [M.C., G.P/ ABSTRACT. We report the case of a boy who developed role in aerobic energy metabolism (1). It consists of multiple a motor neuropathy during infectious episodes at 18 mo copies of three catalytic enzymes: PDH El, which is composed and 3 y of age. When he was 7 y old, he suffered persistent of two a and two p subunits and uses thiamine pyrophosphate weakness and areflexia; his resting lactate and pyruvate as a coenzyme, PDH E2, and PDH E3. An additional protein X values were 3.65 mM and 398 pM, respectively (controls: is involved in the linkage of the different subunits (2). Two 1.1 f 0.3 mM and 90 f 22 pM), and an exercise test regulatory enzymes (PDH kinase and PDH phosphatase) catalyze demonstrated a lactic acidosis (13.6 mM, controls: 6.4 f the interconversion of the active, dephosphorylated and the 1.3 mM) with a high pyruvate level (537 pM; controls: 176 inactive, phosphorylated forms of PDH El (3).
    [Show full text]
  • Function and Structure of Complex Ii of The
    Annu. Rev. Biochem. 2003. 72:77–109 doi: 10.1146/annurev.biochem.72.121801.161700 FUNCTION AND STRUCTURE OF COMPLEX II * OF THE RESPIRATORY CHAIN Gary Cecchini Molecular Biology Division, Veterans Administration Medical Center, San Francisco, California 94121, and Department of Biochemistry and Biophysics, University of California, San Francisco, California 94143; email: [email protected] Key Words succinate dehydrogenase, fumarate reductase, quinone oxidoreductase, reactive oxygen species, respiratory chain f Abstract Complex II is the only membrane-bound component of the Krebs cycle and in addition functions as a member of the electron transport chain in mitochondria and in many bacteria. A recent X-ray structural solution of members of the complex II family of proteins has provided important insights into their function. One feature of the complex II structures is a linear electron transport chain that extends from the flavin and iron-sulfur redox cofactors in the membrane extrinsic domain to the quinone and b heme cofactors in the membrane domain. Exciting recent developments in relation to disease in humans and the formation of reactive oxygen species by complex II point to its overall importance in cellular physiology. CONTENTS OVERVIEW OF MEMBRANE-BOUND RESPIRATORY CHAIN .......... 78 COMPLEX II .......................................... 80 OVERALL STRUCTURE OF COMPLEX II ....................... 83 FLAVOPROTEIN SUBUNIT AND FORMATION OF THE COVALENT FAD LINKAGE............................................ 87 CATALYSIS IN COMPLEX II................................ 91 IRON-SULFUR CLUSTERS OF COMPLEX II AND THE ELECTRON TRANS- FER PATHWAY........................................ 94 MEMBRANE DOMAIN OF COMPLEX II ........................ 95 ROLE OF THE b HEME IN COMPLEX II ........................ 99 RELATION OF COMPLEX II TO DISEASE AND REACTIVE OXYGEN SPECIES ............................................100 CONCLUDING REMARKS .................................104 *The U.S.
    [Show full text]
  • GRACILE Syndrome, a Lethal Metabolic Disorder with Iron
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Am. J. Hum. Genet. 71:863–876, 2002 GRACILE Syndrome, a Lethal Metabolic Disorder with Iron Overload, Is Caused by a Point Mutation in BCS1L Ilona Visapa¨a¨,1,3 Vineta Fellman,7 Jouni Vesa,1 Ayan Dasvarma,8 Jenna L. Hutton,2 Vijay Kumar,5 Gregory S. Payne,2 Marja Makarow,5 Rudy Van Coster,9 Robert W. Taylor,10 Douglass M. Turnbull,10 Anu Suomalainen,6 and Leena Peltonen1,3,4 Departments of 1Human Genetics and 2Biological Chemistry, University of California Los Angeles School of Medicine, Los Angeles; 3Department of Molecular Medicine, National Public Health Institute, 4Department of Medical Genetics, 5Institute of Biotechnology, and 6Department of Neurology and Programme of Neurosciences, University of Helsinki, and 7Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki; 8Murdoch Children’s Research Institute, Melbourne, Australia; 9Department of Pediatrics, Ghent University Hospital, Ghent, Belgium; and 10Department of Neurology, University of Newcastle upon Tyne, Newcastle, United Kingdom GRACILE (growth retardation, aminoaciduria, cholestasis, iron overload, lactacidosis, and early death) syndrome is a recessively inherited lethal disease characterized by fetal growth retardation, lactic acidosis, aminoaciduria, cholestasis, and abnormalities in iron metabolism. We previously localized the causative gene to a 1.5-cM region on chromosome 2q33-37. In the present study, we report the molecular defect causing this metabolic disorder, by identifying a homozygous missense mutation that results in an S78G amino acid change in the BCS1L gene in Finnish patients with GRACILE syndrome, as well as five different mutations in three British infants.
    [Show full text]
  • Citrate Synthase a Mitochondrial Marker Enzyme
    Oroboros Protocols Enzymes Mitochondrial Physiology Network 17.04(04):1-12 (2020) Version 04: 2020-04-18 ©2013-2020 Oroboros Updates: http://wiki.oroboros.at/index.php/MiPNet17.04_CitrateSynthase Laboratory Protocol: Citrate synthase a mitochondrial marker enzyme Eigentler A1,2, Draxl A2, Gnaiger E1,2 1D. Swarovski Research Laboratory Dept Visceral, Transplant and Thoracic Surgery Medical Univ Innsbruck, Austria www.mitofit.org 2Oroboros Instruments High-Resolution Respirometry Schöpfstrasse 18, A-6020 Innsbruck, Austria Email: [email protected]; www.oroboros.at 1. Background 1 1.1. Enzymatic reaction catalyzed by citrate synthase 2 1.2. Principle of spectrophotometric enzyme assay 2 1.3. Temperature of enzyme assay 3 2. Reagents and buffers 3 2.1. Prepare every month new and store at 4 °C 3 2.2. Prepare 12.2 mM acetyl-CoA, store at -20 °C 3 2.3. Prepare fresh every day 3 2.4. Chemicals 4 3. Sample preparation 4 4. Measurement: Spectrophotometer HP8452A Diode Array 6 4.1. Measurement of CS activity in 1 mL cuvette 6 4.2. Blank measurement 6 4.3. Sample measurement 7 4.4. Experimental procedure 7 5. Data analysis: calculation of specific CS activity 8 5.1. Absorbance, concentration and rate of reaction 8 5.2. Specific enzyme activity: reaction rate per unit sample 8 6. Normalization of respiratory flux for CS activity 9 6.1. Flow per instrumental chamber, IO2 9 6.2. Flux per chamber volume, JV,O2 10 6.3. Flow per experimental object, IO2/N 10 6.4. Flux per sample mass, JO2/m 10 7. References 10 8.
    [Show full text]
  • Caspase-6 Induces 7A6 Antigen Localization to Mitochondria During FAS-Induced Apoptosis of Jurkat Cells HIROAKI SUITA, TAKAHISA SHINOMIYA and YUKITOSHI NAGAHARA
    ANTICANCER RESEARCH 37 : 1697-1704 (2017) doi:10.21873/anticanres.11501 Caspase-6 Induces 7A6 Antigen Localization to Mitochondria During FAS-induced Apoptosis of Jurkat Cells HIROAKI SUITA, TAKAHISA SHINOMIYA and YUKITOSHI NAGAHARA Division of Life Science and Engineering, School of Science and Engineering, Tokyo Denki University, Hatoyama, Japan Abstract. Background: Mitochondria are central to caspases (caspase-8 and -9) that activate effector caspases (1). apoptosis. However, apoptosis progression involving Caspases are constructed of a pro-domain, a large subunit, and mitochondria is not fully understood. A factor involved in a small subunit. Upon caspase activation, cleavage of the mitochondria-mediated apoptosis is 7A6 antigen. 7A6 caspase occurs. Caspase-6 and -7, which are effector caspases, localizes to mitochondria from the cytosol during apoptosis, each have a large subunit that is 20 kDa (p20) and a small which seems to involve ‘effector’ caspases. In this study, we subunit that is 10 kDa (p10), but caspase-3, which is also an investigated the precise role of effector caspases in 7A6 effector caspase, has a large subunit of 17 kDa and a small localization to mitochondria during apoptosis. Materials and subunit of 12 kDa (p12) (2-4). Moreover, the large and small Methods: Human T-cell lymphoma Jurkat cells were treated subunits of caspase-6 and -7 are connected by a linker, but with an antibody against FAS. 7A6 localization was analyzed caspase-3 does not have a linker (Figure 1). The difference by confocal laser scanning microscopy and flow cytometry. between effector and initiator caspases is that the pro-domain Caspases activation was determined by western blot of an initiator caspase is long and that the pro-domain of an analysis.
    [Show full text]